Medical Technology Innovation Shift: Who Will Lead the Next Wave of Device Growth?

Introduction

Over the past decade, the innovation landscape in the HealthTech sector has been undergoing a subtle yet profound shift. For a long time, large medical technology companies, backed by massive R&D budgets and mature commercialization pathways, dominated the clinical trials and market approvals of medical devices. However, the latest industry data shows that the locus of innovation is gradually shifting toward private enterprises and mid-cap companies—a change that will redefine the next era of medical device growth.

Industry Background

According to the latest industry report released by RSM US, overall R&D spending by publicly listed medical technology companies has continued to rise over the past decade, especially during 2020–2021, when a large inflow of capital drove a surge in R&D investment. Yet this growth has been uneven: R&D budgets at large- and mid-cap companies are still increasing, while small-cap listed companies—after experiencing nearly 50% R&D spending growth between 2016 and 2023—have seen R&D investment decline over the past two years due to difficulties in accessing capital, directly affecting the pace of their clinical trials and product approvals.

Key Developments

The sponsors of clinical trials are undergoing significant changes. In 2010, large medical technology companies sponsored about 40% of industry-sponsored clinical trials; by 2025, that share had fallen to 25%. At the same time, the number of clinical trials sponsored by private medical technology companies has continued to climb, suggesting that the source of innovation is shifting from giants to more agile emerging companies.

Device approval data also confirms this trend. After reaching a peak of nearly 6,000 premarket approvals (PMAs) and 510(k) clearances in 2017, the number of approved devices each year has declined steadily, falling to 4,005 in 2025. Multiple factors are behind this: a tightening financing environment in the medical technology industry, the increased approval complexity of technologies such as AI-assisted devices, and staffing constraints at the U.S. FDA's Center for Devices and Radiological Health (CDRH). According to the Minneapolis Star Tribune, by the end of 2024, the number of pending applications for higher-risk devices had increased, but approvals in the first quarter of 2025 were lower than in the same periods of 2024 and 2023.

In addition, the proportion of device applications from Europe has risen. Since the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) were introduced in 2017, many companies have turned to the United States when considering their first launch market. In recent years, European companies have accounted for a growing share of 510(k) and PMA applications in the U.S. That said, U.S. companies obtain PMA approval about one month faster on average than European companies.

Notably, mid-cap and private companies have seen their share of approved devices continue to rise, while approval numbers at large companies have steadily declined. This may reflect a market stratification—large companies are more focused on adapting existing technology platforms to meet evolving healthcare needs, launching fewer devices but with greater innovativeness. However, combined with R&D and clinical trial data, private and mid-cap companies are actively positioning themselves for the next generation of innovation and are better placed to capture new market demand.## Market Impact

The innovation-driven shift will have a profound impact on the healthcare industry. First, private and mid-sized companies will become the main drivers of new device launches, requiring investors and acquirers to pay closer attention to early-stage technologies. Second, large medical technology companies may need to supplement their R&D pipelines through strategic partnerships or acquisitions to counter pressure from agile competitors. In addition, as Medical AI and Digital Health devices become increasingly complex, regulators may face greater review challenges, and the industry will need more efficient approval pathways.

Challenges and Risks

Although the innovation landscape is tilting toward new players, challenges remain significant. Capital constraints are still the biggest obstacle for private companies, especially in the later stages of clinical trials, where funding needs surge dramatically. Regulatory complexity is also rising—AI-enabled medical devices require entirely new evaluation frameworks, and CDRH's staffing limitations will be difficult to resolve in the short term. Furthermore, data security and privacy compliance, along with regulatory differences across international markets, impose additional burdens on globalized medical technology companies.

Future Outlook

Looking ahead three to five years, medical technology innovation will take on a more diversified landscape. AI-assisted diagnosis, wearable monitoring devices, surgical robots, and other segments are expected to become breakthrough areas for private companies. On the regulatory front, the FDA and other international bodies may introduce flexible frameworks adapted to the rapid iteration of AI, balancing innovation and safety. At the enterprise level, the traditional "self-development–approval–launch" model may run in parallel with the "collaboration–incubation–M&A" path, as large companies integrate emerging technologies into their own systems through open innovation platforms and venture capital.

Conclusion

The direction of capital flows is already clear: venture capital and private equity are increasing their investment in private medical technology companies, and this trend will force large companies to obtain innovative assets through M&A or licensing. As the main drivers of medical technology innovation shift, the industry will enter a stage of development driven jointly by diverse participants. The answer to future device growth may not lie within the giants themselves, but among those companies that dare to challenge traditional paths.